Kornimate/medical-research-clean huggingface dataset:
low dose il2 immunotherapy in ad

Conditions: Alzheimer Disease

Summary: neuroinflammation is a significant component of alzheimer disease (ad). our data demonstrated compromised regulatory t cells (tregs) phenotype and suppressive function in ad patients, skewing the immune system toward a proinflammatory status and potentially contributing in disease progression. low dose interleukin-2 (il-2) is now viewed as a very promising immunoregulatory drug having the capacity to selectively expand and restore functional tregs. this study is a phase i open-label study to assess subcutaneous interleukin-2 (il2) safety and potential efficacy as a treg inducer in ad. 8 alzheimer dementia patients with mild clinical dementia will be recruited into the study. the baseline cognitive status will be evaluated in these patients. monthly five-day-courses of subcutaneous il2 (1mui/day) will be administered for a total of 4 months. changes in tregs from pre to post injections will be measured during the study period. the expected time participants will be in the study is 6 months.


Eligibility criteria:
inclusion criteria: * diagnosis of probable alzheimer disease according to national institute on aging-alzheimer's association (nia-aa) criteria13. * male or female age 60 to 86 years * clinical dementia rating scale of 1 * total bilirubin less than or equal to 1.5mg/dl * alanine aminotransferase level (alt) less than or equal to five times normal, albumin greater than or equal to 3.0gm/dl * serum creatinine less than 1.5 mg/dl * english language speaking * a family member or caretaker who is expected to be consistently available, administer study drug and attend study visits throughout the study. exclusion criteria: * serious, active bacterial, fungal or viral infection * severe pulmonary dysfunction. fev1 and fvc less than 40% of predicted (or 3 sd below normal) at baseline, if a pulmonary function test is clinically indicated. hx of intubation for \>72 hours. * severe cardiac dysfunction defined as left ventricular ejection fraction \<40% if an echocardiogram is medically indicated to clarify ongoing symptoms or ekg findings.; a history of non-controlled cardiac arrhythmias; history of cardiac tamponade; unstable angina or mi in the last 3 months * hypersensitivity or allergy to il-2 * bowel ischemia/perforation, gi bleeding requiring surgery * resistant seizures, history of coma or toxic psychosis lasting \>48 hours * patients with white blood count (wbc) \<4,000/mm3; platelets \<100,000/mm3; hematocrit (hct) \<30%.
reference range analysis of the entegrion point of care coagulation monitor (pcm™) in healthy volunteers

Conditions: Coagulation

Summary: this study is intended to define the pcm normal laboratory range.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. body mass index (bmi) ≥ 19 and ≤ 30 kg/m2m with body weight ≥ 50 kg (106 lb) 3. normal vital signs at screening exclusion criteria: 1. current daily tobacco use or previous recreational drug use 2. pregnant or lactating at the time of the study 3. currently taking any medications known to affect coagulation 4. history of excessive bleeding from minor trauma that required medical attention, spontaneous nose bleeds that required medical attention or multiple spontaneous abortions, liver disease, blood related diseases, congenital or acquired coagulopathies or thromboembolic diseases 5. current diagnosis of cancer
analysis of trends over time of hepatitis related incidence in panama

Conditions: Hepatitis

Summary: the purpose of this study is to analyze the incidence of baseline hepatitis related outcomes (viral hepatitis a and unspecified viral hepatitis) together with the current frequency of the same outcome after introduction of havrix™ in panama.

in this study, systematic review of the databases of epidemiologic surveillance system (ministry of health), for hepatitis related outcomes will be performed. the analysis will be performed by age group, years and country region.

Eligibility criteria:
inclusion criteria: * hepatitis related outcomes occurred during the period analyzed and registered in the epidemiologic surveillance system of the ministry of health, will be collected for the study exclusion criteria: * not applicable
tissue lesions in exercise related ischemia

Conditions: Ischemia; Peripheral Artery Disease

Summary: the purpose of this study is to evaluate the effect of muscle ischemia during claudication on mitochondrial function. comparison to patients with arterial disease but absence of lower limb claudication (cardiac group) feasibility study.

assess the feasibility of the study of micro-vascular function and mitochondrial on muscle sample (sartorius) in a group of arterial disease and non arteriopathy group. analysis of the activity of mitochondrial chain immunochemistry of tissue markers

Eligibility criteria:
inclusion criteria: * intervention for femoropopliteal bypass (pad group) * intervention for saphenous withdrawal for coronary bypass surgery (cardiac group) exclusion criteria: * participate in another biomedical research * pregnant woman
oxidative stress in chronic kidney disease: diet and exercise

Conditions: Chronic Kidney Disease

Summary: the central aim of this study is to improve understanding of how metabolic pathways that contribute to adiposity also amplify risks of kidney disease progression and cardiovascular disease in subjects with moderate to severe ckd. in order to achieve this goal, we propose the following aims through a randomized 2x2 factorial design trial in subjects with moderate to severe ckd: (a) to assess the feasibility of implementing aerobic exercise and caloric restriction interventions, and (b) to examine the effects of aerobic exercise and caloric restriction on a metabolic risk profile, including systemic measures of oxidative stress, inflammation, insulin resistance, and endothelial dysfunction. hypothesis: we hypothesize that implementation of caloric restriction and aerobic exercise is feasible and can improve the metabolic milieu (as assessed by measures of oxidative stress, inflammation, insulin resistance, and endothelial dysfunction) in subjects with moderate to severe ckd. interim analysis may be performed (no specific plan at this time).


Eligibility criteria:
inclusion criteria: * stage iii-iv ckd measured by the mdrd equation with egfr 15-60 ml/min/1.73m2; * age 18-75 years; * bmi ≥ 25; * life expectancy ≥ 1 year; * ability to understand and provide informed consent. exclusion criteria: * any acute inflammatory condition (including chronic infection requiring treatment, and collagen vascular disease including active gout); * pregnancy; * taking high-dose anti-oxidants (vitamin e or c); * chronic use of anti-inflammatory medication except low dose (\< 10mg/d) prednisone and aspirin (\< 100 mg/day); * significant cardiac or vascular disease (symptomatic disease or cv event including congestive heart failure within 6 months); * significant occlusive atherosclerotic disease or ischemic disease (on non-invasive or invasive diagnostic procedures); * significant physical immobility or disabilities (joint replacement, muscular disorders); * type i diabetes mellitus, or type ii requiring insulin therapy; * history of poor adherence to medical regimen; * those subjects who have a diagnosis of atrial fibrillation or a pacemaker will be allowed in the study but will not undergo arterial tonometry (pwv) studies.
neurofeedback and working memory training for children and adolescents with adhd

Conditions: Attention Deficit Disorder

Summary: the purpose of this study is to investigate if neurofeedback and working memory training improves core symptoms of adhd in children and adolescents.

this study investigates two types of neurofeedback (nf), one well-established and well-researched protocol called slow cortical potential nf (scp), and a newer and less researched, yet popular among private clinicians, the so-called live z-score training (lzt). these methods are compared to working memory training (wmt) and a passive control condition, treatment-as-usual only (tau). the active conditions (scp/lzt/wmt) are delivered high frequent, with 5 sessions/week, for a total of 25 sessions. outcomes measures are taken at preintervention and postintervention, as well as at a 6-month follow-up assessment.

Eligibility criteria:
inclusion criteria: * clinical ad/hd diagnose according to dsm-iv-tr and k-sads interview, 9-17 years old, unmedicated or under stable medication with stimulants or corresponding since at least one month. exclusion criteria: * iq \<70 (wisc-iv or wais-iv), clinically instable psychiatric state e.g. severe depression, ocd, self-injurious behaviour, bipolar disorder, severe somatic (neurologic) disease, very limited knowledge in the swedish language.

Keywords: ad/hd in children and adolescents
supervised exercise as a therapeutic strategy for interstitial cystitis/bladder pain syndrome

Conditions: Interstitial Cystitis; Bladder Pain Syndrome

Summary: in this study, the efficacy of exercise to improve interstitial cystitis/bladder pain syndrome symptoms and quality of life will be investigated.

effective treatment for symptoms associated with interstitial cystitis/bladder pain syndrome is a significant clinical challenge due to the lack of insight into disease etiology/pathophysiology, costly and potentially invasive procedures, and a lack of research into potential therapeutics. the primary objective of this study is to determine if a supervised exercise program by a trained exercise physiologist can relieve pain and improve urinary and bladder symptoms in patients with interstitial cystitis/bladder pain syndrome. this has the potential to open enormous future avenues of research, save both patients and the healthcare system cost, and most importantly improve patients' lives. a second objective of this study is to determine if exercise alters depressive symptoms, often a comorbid diagnosis, in patients with interstitial cystitis/bladder pain syndrome. a third objective of this study is to examine urinary markers of inflammation before and after exercise in patients with interstitial cystitis/bladder pain syndrome.

Eligibility criteria:
inclusion criteria: * adult females (\>18 years and \<80 years) with a previously established clinical diagnosis of interstitial cystitis/bladder pain syndrome (ic/bps) will be eligible to participate * must speak english * the clinical diagnosis of ic/bps will be based on the recently published american urological association guidelines definition: "an unpleasant sensation (pain, pressure, or discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms for more than six weeks duration, in the absence of infection or other identifiable causes" * the diagnosis will be confirmed by a urologist who specializes in the treatment of patients with ic/bps exclusion criteria: * study participants must be fully ambulatory without the use of a cane, walker, or wheelchair * study participants must be able to tolerate moderate aerobic exercise. it will also be required that a physician clear any subjects entering the exercise program who have signs and symptoms suggestive of cardiovascular, cerebrovascular, metabolic, or renal disease and have been active 3 days per week for 30 minutes each day * any history of bladder cancer, uterine cancer, ovarian cancer, vaginal cancer, the current placement of a catheter, urethral diverticulum, spinal cord injury, stroke, parkinson's disease, multiple sclerosis, spina bifida, cyclophosphamide treatment, radiation cystitis, bladder tuberculosis, or are experiencing an active genital herpes episode * pregnant women are not eligible for this study

Keywords: exercise interstitial cystitis bladder
potential acceptance of covid-19 vaccines in healthcare workers in egypt

Conditions: Covid19

Summary: the covid-19 pandemic is expected to remain as a public health threat and economic burden all over the world. the available proposed vaccines are still lacking large randomized controlled trials testing its efficacy and safety. thus, the acceptance of vaccination between citizens as well as healthcare workers is not guaranteed. as the vaccine is starting to be distributed the acceptance of healthcare givers should be measured as they are usually the front line facing the problem and they have a responsibility to explain the need of immunization to the rest of population. strategies to enhance the acceptance and trust of the available vaccines may be needed.


Eligibility criteria:
inclusion criteria: healthcare workers - exclusion criteria: * none healthcare workers

Keywords: covid-19 healthcare workers covid-19 vaccines vaccine acceptance
umbilical cord mesenchymal stem cell secretome in severe erectile dysfunction non-responsive to sildenafil

Conditions: Erectile Dysfunctions

Summary: the study is an experimental pre-post-test design involving 10 patients with severe ed non-responsive to sildenafil. safety parameters included pain, hematoma, local bleeding, and infection, while efficacy was measured using the iief-5 questionnaire, ehs, and morning erection.

the study employed umbilical cord mesenchymal stem cell secretome, one intravenous injection containing one ml into two locations, one injection in one cavernous body, and three direct follow-ups with the patient: directly after injection, one day and one month after the injection.

Eligibility criteria:
inclusion criteria: * men aged 40-65 years who undergo treatment at the andrology clinic of rsud dr. soetomo. * severe erectile dysfunction caused by organic factors for at least 6 months, based on an iief-5 score of 5-7 * history of undergoing treatment with sildenafil 100 mg for four sessions. * evaluation of iief-5 score \< 22 and not meeting the mcid criteria, defined as an iief-5 score increase of less than 4 * type ii diabetes melitus with an hba1c test result of \< 7%. * laboratory test results for liver function (sgot and sgpt) and kidney function (urea and creatinine) are within normal limits. * patients with undergoing treatment with antidepressant. exclusion criteria: * anatomical abnormalities of the penis that are clinically visible, such as peyronie's disease, a history of priapism, a history of penile implants, skin irritation, and lesions in the area surrounding the penile skin. * active and significant systemic or local infection. * history of bleeding or blood clotting disorder therapy. * history of systemic autoimmune disorders and immunosuppressive treatment * history of prostate surgery, history of malignancy, or a psa level \> 4 ng/ml. * untreated hypogonadism or low serum total testosterone (\<200 ng/dl). * uncontrolled hypertension or hypotension (systolic blood pressure \>170 or \ 100 or \<50 mmhg). * unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within the last 6 months, and congestive heart failure).

Keywords: erectile dysfunction secretome uc-msc
bladder training in radical prostatectomy

Conditions: Urinary Incontinence; Quality of Life; Lower Urinary Tract Symptoms

Summary: radical prostatectomy is the gold standard in the treatment of patients with localized prostate cancer. urinary incontinence, which is common after surgery, can affect the quality of life of men negatively. there are various attempts to prevent and treat urinary symptoms after radical prostatectomy.the aim of this study is to evaluate the effect of the structured bladder training program on lower urinary tract symptoms and quality of life in patients undergoing radical prostatectomy.


Eligibility criteria:
inclusion criteria: * being over the age of 40 years * being male * being with localized prostate cancer * undergoing open radical prostatectomy * no preoperative urinary incontinence * being body mass index\> 30 kg/m2 * agreeing to participate in the research * being literate exclusion criteria: * having a congenital disorder of the urinary system * having neurological disorders * having a history of transurethral resection of the prostate * having communication and mental impairment * inability to do pelvic floor muscle exercises
investigating the effect of onyx sorghum on blood glucose in individuals with type 2 diabetes

Conditions: Diabetes Type 2

Summary: to evaluate the effect of onyx sorghum on blood glucose levels in patients with type 2 diabetes (t2dm).

the plan is to study 24 participants with t2dm, who are otherwise healthy. the study will be double-blinded and randomized. participants will first attend a screening visit (visit #1) to determine eligibility. then, eligible participants will be asked to wear a freestyle libre pro continuous glucose monitor (cgm) for up to 14 days (visit #2). after this 14-day cgm session, participants will be randomly assigned (1:1) to one of two groups that will receive: 1) food products containing onyx sorghum (onyx group) or 2) food products with wheat flour (control group). the diet intervention will last a total of 28 days. participants will have weekly visits to pick up food and bi-weekly blood draws (no more than 20ml at each visit). they will also be asked to wear the cgm throughout the diet intervention and will record their food intake in a daily food diary to confirm that the diet intervention is being followed.

Eligibility criteria:
inclusion criteria: * ages 30-65 years * a1c \< 8.5% * bmi \> 18.5 exclusion criteria: * known malignancy, anemia, kidney disease, and/or liver disease * untreated thyroid disease * uncontrolled hypertension * initiation of any anti-diabetes medications within the last 3 months * greater than 5% change in weight in the last 3 months * current or recent steroid use in the last 3 months * for women: pregnancy or breastfeeding
effectiveness of narrow margins in patients with low-risk basal cell carcinoma undergoing surgery

Conditions: Skin Basal Cell Carcinoma

Summary: this clinical trial studies the effectiveness of narrow margins in patients with low-risk basal cell carcinoma undergoing surgery to remove skin lesions on the face. a margin is the area of normal tissue around a tumor taken out during surgery to make sure all of the cancer is removed. this clinical trial studies tissue samples to determine the least amount of tissue that must be removed to give an acceptable cure rate. this may allow less normal tissue to be removed from patients and may be a less expensive surgery.

primary objectives: i. to determine the success rate of narrow margin excisions of low-risk facial basal cell carcinoma (bcc). secondary objectives: i. to determine the narrowest excision margin for low-risk facial bcc that gives an acceptable (95%) cure rate over a 3 year follow-up period.

Eligibility criteria:
inclusion criteria: 1. location 1. area m (cheeks, forehead, scalp \& neck) tumor size \< 10 mm 2. area h (central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular \& postauricular, temple \& ear) tumor size \< 6 mm 2. well-defined borders 3. primary bcc 4. patient is not immunosuppressed 5. there has not been prior radiotherapy to the site 6. nodular subtype 7. no perineural involvement-(no neurological deficits grossly) - exclusion criteria: 1. location 1. area m tumor size \> or = to 10 mm 2. area h tumor size \> or = to 6 mm 2. poorly defined borders 3. recurrent bcc 4. patient is immunosuppressed 5. there has been prior radiotherapy to the site -
anterior knee pain between unisex knee prosthesis vs gender specific knee prosthesis following mis tka

Conditions: Osteo Arthritis Knee; Knee Pain Chronic

Summary: unisex knee prosthesis and patient specific knee prosthesis has the same anterior knee pain and patellar tracking

background:the anterior knee pain (akp) is one of major problem of tka. the incidence of anterior knee after tka was 4% to 49%. the cause of akp after tka from surgical technique errors including joint line elevation, instability, malalignment of prosthesis, and maltracking of patella. however, akp still has presented even high volume surgeon that prosthesis had good alignment and good stability, one of the risk factor is female. due to female has higher q-angle, greater anteroposterior (ap)/mediolateral(ml) ratio, smaller anterior condyle, and trochlea has higher degree of valgus angle than male. therefore, female should has akp even surgery with good surgical technique. the gender specific knee prosthesis was design for female to restore q-angle, reduce anteroposterior (ap)/mediolateral(ml) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. for these reasons, the gender specific knee prosthesis should reduce akp and improve patellar tracking in female. and there is no study to compare akp and patellar tracking between unisex knee prosthesis and gender specific knee prosthesis following minimally invasive surgery (mis) tka. investigators asked whether akp and patellar tracking differ between unisex knee prosthesis and gender specific knee prosthesis following mis tka with patellar resurfacing. methods:the participants were randomized into 2 groups (gp) with computer program to make a list of random numbers of participant. gp1 was gender specific knee prosthesis; consisted of 40 participants (40 knees) and gp2 was unisex knee prosthesis; consisted of 40 participants (40 knees). the sample size was calculate base on anterior knee pain after tka with a risk difference of 27% (3% versus 20%) (1,3). the 40 participants from each group would have 90% power at the 5% significant level. patrticipants were follow up at 2 wks, 6 wks, 3 mo, 6mo, 1 year and 2 years. at each follow up, the % anterior knee pain, vas for anterior knee pain were record. the knee society score also was recorded and compared between two group. all participants were operated with same surgeon and same instrumentation.

Eligibility criteria:
inclusion criteria: aymptomatic knee oa with * varus deformity \< 30 degrees * range of motion \> 90 degrees * flexion contracture \< 20 degrees * recurvatum \< 20 degrees exclusion criteria: * gout * postraumatic arthritis * osteonecrosis of knee * inflammatory joint disease

Keywords: anterior knee pain gender knee prosthesis patellar tracking unisex knee prosthesis total knee arthroplasty patellar resurfacing